Deepali Gupta, Avi W Burstein, Dana C Schwalbe, Kripa Shankar, Salil Varshney, Omprakash Singh, Subhojit Paul, Sean B Ogden, Sherri Osborne-Lawrence, Nathan P Metzger, Corine P Richard, John N Campbell, Jeffrey M Zigman. Ghrelin deletion and conditional ghrelin cell ablation increase pancreatic islet size in mice.The Journal of clinical investigation. 2023, 133 (24):
Xiaobo Wang, Shuang Geng, Junchen Meng, Ning Kang, Xinyi Liu, Yanni Xu, Huiyun Lyu, Ying Xu, Xun Xu, Xinrong Song, Bin Zhang, Xin Wang, Nuerdida Nuerbulati, Ze Zhang, Di Zhai, Xin Mao, Ruya Sun, Xiaoting Wang, Ruiwu Wang, Jie Guo, S R Wayne Chen, Xuyu Zhou, Tie Xia, Hai Qi, Xiaoyu Hu, Yan Shi. Foxp3-mediated blockage of ryanodine receptor 2 underlies contact-based suppression by regulatory T cells.The Journal of clinical investigation. 2023, 133 (24):
Deborah A Knight, Shin Foong Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok, Ashley Cass, Nicole M Haynes, Kathryn Kinross, Hideo Yagita, Richard C Koya, Thomas G Graeber, Antoni Ribas, Grant A McArthur, Mark J Smyth. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.The Journal of clinical investigation. 2023, 133 (24):
Amanda Macamo, Jan Beckervordersandforth, Axel Zur Hausen. Metagenome analyses identify human endogenous retrovirus-K113 (HML-2) subtype in glioblastoma.The Journal of clinical investigation. 2023, 133 (24):
Sean Sachdev. A friend in a forest of radiation-immune interactions: BAMBI improves antitumor effects by limiting radioresistance.The Journal of clinical investigation. 2023, 133 (24):
Michael R Schlabach, Sharon Lin, Zachary R Collester, Christopher Wrocklage, Sol Shenker, Conor Calnan, Tianlei Xu, Hugh S Gannon, Leila J Williams, Frank Thompson, Paul R Dunbar, Robert A LaMothe, Tracy E Garrett, Nicholas Colletti, Anja F Hohmann, Noah J Tubo, Caroline P Bullock, Isabelle Le Mercier, Katri Sofjan, Jason J Merkin, Sean Keegan, Gregory V Kryukov, Caroline Dugopolski, Frank Stegmeier, Karrie Wong, Fiona A Sharp, Louise Cadzow, Micah J Benson. Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens.The Journal of clinical investigation. 2023, 133 (24):